Cephalon has provided results from a pivotal clinical trial of lestaurtinib (CEP-701), in patients with relapsed acute myelogenous leukemia (AML). Lestaurtinib is a potent inhibitor of several tyrosine
The Mayo Clinic has reported data on a prostate cancer study with ipilimumab, a fully human antibody that binds to CTLA-4 (cytotoxic T lymphocyte-associated antigen 4), a molecule
Forest Laboratories has provided positive results from two global multi-center phase-III studies of ceftaroline, for the treatment of community-acquired bacterial pneumonia (CABP). The top-line data in each of
Non-GAAP adjusted earnings from continuing operation per ADS increased by about 80% year-over-year to about RMB15.8 for fiscal 2008. For the fourth quarter of fiscal 2008, Revenues from
Cytokinetics has initiated first-time-in-humans, phase-I clinical trial of CK-2017357 in healthy male volunteers. CK-2017357 is a fast skeletal muscle troponin activator, and is the lead drug candidate of
Seattle Genetics has initiated phase-II clinical trial of SGN-35 for patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). SGN-35 is an antibody-drug conjugate (ADC) that
Pfizer has announced that the US Securities and Exchange Commission (SEC) has declared effective Pfizer’ Registration Statement on Form S-4. The Form S-4 registers with the SEC Pfizer’s
Takeda has launched two new dose strengths of Blopress Plus in Germany. These are fixed-dose combinations of 32mg candesartan. The maximum doses authorized in Europe are with 25mg
Canada-based Paladin Labs and Sylphar have entered into an agreement to develop and market an oral dissolving teeth whitening film strip in Europe. Under the agreement, Sylphar and
Antares Pharma’ partner BioSante has said that the LibiGel Safety Study External Executive Committee has recommended continuation of the LibiGel phase-III clinical program. The decision of the committee
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.